Purpose: Little is known about the longitudinal patterns of buprenorphine adherence among pregnant women with opioid use disorder, especially when late initiation, nonadherence, or early discontinuation of buprenorphine during pregnancy may increase the risk of adverse outcomes. We aimed to identify distinct trajectories of buprenorphine use during pregnancy, and factors associated with these trajectories in Medicaid-enrolled pregnant women. Results: Six distinct trajectories were identified. Four groups initiated buprenorphine during the first trimester of the pregnancy (early initiators): 31.6% with persistently high adherence, 15.1% with moderate-to-high adherence, 10.5% with declining adherence, and 16.7% with early discontinuation. Two groups did not initiate buprenorphine until midsecond or third trimester (late initiators): 13.5% had moderate-to-high adherence and 12.6% had low-to-moderate adherence. Factors significantly associated with late initiation and discontinuation were younger age, non-white race, residents of rural counties, fewer outpatient visits, more frequent emergency department visits and hospitalizations, and lower buprenorphine daily dose.
| INTRODUCTION
In the last 2 decades, opioid use disorder (OUD) and overdose deaths among reproductive-aged and pregnant women have increased dramatically in the United States.
1 Pregnant women with OUD have an increased risk of adverse maternal, obstetric, and neonatal outcomes (eg, preterm birth, fetal growth restriction). 2, 3 Opioid agonist therapy has been shown to reduce illicit drug use and the risk of infection and improve adherence to prenatal care, maternal nutrition, and infant birth weight. 4 Methadone has been the standard therapy for pregnant women with OUD for over 40 years. Emerging evidence supports buprenorphine (without naloxone) as an alternative first-line therapeutic option in pregnancy. 5 A multicenter, randomized controlled trial demonstrated that buprenorphine-exposed infants had a shorter length of hospital stays, shorter treatment durations for neonatal abstinence syndrome (NAS), and a lower cumulative morphine dose to treat NAS compared to methadone-exposed newborns. 5 Other advantages of buprenorphine over methadone for pregnant women include a lower risk of overdose and fewer drug interactions. 6 Little evidence exists on longitudinal utilization and adherence patterns of buprenorphine therapy during the pregnancy and postpartum periods among pregnant women with OUD. Typical measures of adherence (eg, average over a year period) or simple criteria of discontinuation (eg, with a gap ≥30 days) do not capture all clinically relevant measures of buprenorphine use such as the timing and dynamic patterns of treatment initiation, nonadherence, and discontinuation during pregnancy.
Group-based trajectory models with intuitive graphical results can leverage the dynamic nature of buprenorphine use and identify subgroups with similar change over time. [7] [8] [9] In our prior work of 10 945
Pennsylvania Medicaid beneficiaries newly initiating buprenorphine, 8 we successfully identified 6 distinct treatment trajectories during the first year of treatment using group-based trajectory models and examined their association with subsequent health outcomes. For example, refilling buprenorphine intermittently was associated with a 24%
higher risk of emergency department (ED) visits. Yet, our prior work largely focused on nonpregnant beneficiaries and did not examine timing of initiation and discontinuation patterns of buprenorphine during pregnancy and postdelivery. Therefore, we aimed to identify dis- buprenorphine prescription, we excluded 221 women who also received methadone during pregnancy (168 switching from buprenorphine to methadone, 15 using methadone prior to buprenorphine, and 38 switching between methadone and buprenorphine for multiple times) to avoid misclassification of treatment switching as nonadherence or discontinuation of OUD treatment. Global reimbursement for methadone in Medicaid also imposes a challenge on measuring adherence to methadone in claims data.
We identified each patient's delivery dates and their birth outcomes, and excluded those who only had induced/spontaneous abortions (Appendix Figure S1 ). According to the US National Committee for Quality Assurance (NCQA)'s quality measures of prenatal and postpartum care, we used 280 days prior to the delivery date as the estimated conception date. 13 Patients were required to have continuous
KEY POINTS
• Six buprenorphine treatment trajectories with different adherence levels were identified among pregnant Medicaid beneficiaries.
• A quarter of pregnant women did not initiate buprenorphine until midsecond or third trimester.
• Factors significantly associated with late initiation and discontinuation were younger age, non-white race, residents of rural counties, having fewer outpatient visits, more frequent emergency department visits and hospitalizations, and lower buprenorphine daily dose.
• Understanding distinct buprenorphine trajectories and associated factors may better guide buprenorphine treatment, integrate behavioral treatment with obstetrical/gynecology care, and target interventions among pregnant women.
Medicaid enrollment during the first trimester (ie, 176 to 280 days prior to delivery) and 43 days prior to delivery and 12 weeks after delivery to obtain information on predictor variables and allow for complete follow-up. 13 The 12-week postdelivery period was chosen because pregnant women in Pennsylvania Medicaid, like many other states, have coverage until 12 weeks after delivery, and this window was considered as clinically reasonable for a postpartum visit (which is recommended at 6 weeks). We followed each patient's prescription buprenorphine fills from the estimated conception date through 12 weeks following the delivery date. When women (n = 407) had multiple pregnancy episodes with buprenorphine treatment during the study period, only the first episode was included in the analysis.
The final analytic sample included 2361 women. (1-365). In each model, we used the most flexible functional form of time to allow the trajectories to emerge from the data. Output of trajectory models includes estimated probabilities of group membership for each individual, and estimated trajectory curves over time. 17, 18 We selected the final model based on a combination of (1) the Bayesian information criterion (BIC), wherein the largest value indicates the best-fitting model, (2) an estimated proportion of each trajectory group that was sufficiently large (>0.05), and (3) application of Nagin's criteria to assess final model adequacy. 19 The Nagin's criteria of a wellperformed trajectory model includes an average posterior probability ≥0.7 for all groups, odds correct classification ≥5.0 for all groups, estimated probability of membership in each group close to the proportion of sample assigned to each group, and narrow confidence intervals. 19 These models were estimated using STATA 14.0 (StataCorp LP, College Station, TX) and the TRAJ macro (free download at http://www.andrew.cmu.edu/user/bjones).
| Factors associated with different buprenorphine trajectories
After determining the most appropriate trajectory models, we compared the patient characteristics across identified trajectories with X 2 test and analysis of variance, as appropriate. We then examined the association between the membership in a trajectory group and the factors that were significantly different across trajectories from univariate analyses using a multivariable multinomial logistic regression model. We reported adjusted odds ratios (ORs) with 95% confidence intervals (CI). Statistical significance was defined as 2-tailed P < .05.
Based on prior studies of buprenorphine therapy for OUD and medication adherence, Table S1 for the detailed diagnosis and procedure codes).
Health service use factors included any inpatient utilization, number of emergency department (ED) visits, number of outpatient visits, number of other prescriptions with unique ingredients (as a proxy measure of disease and medication complexity), and number of unique prescribers for nonbuprenorphine prescriptions. We also calculated buprenorphine average daily dose (mg/day), maximum increase in buprenorphine dose (mg), number of unique buprenorphine prescribers, and average proportion of days covered (PDC) from estimated conception date to 12 weeks postdelivery. Finally, we measured whether patients received any behavioral counseling as proxy of quality of care for their OUD during the pregnancy. 32 We also examined whether women received any drug urine tests during pregnancy although false positive results from urine drug testing raise concerns regarding negative consequences (eg, accusation of child abuse/neglect by state laws). 33 
| Sensitivity and post hoc analyses
Women with OUD eligible for Medicaid due to pregnancy may have either no or a very short look-back period prior to the estimated conception date during which factors prior to pregnancy can be measured.
This limited our ability to assess the prediction accuracy that was possible before observing any follow-up and to avoid factors such as changes in patient health status that may themselves be consequences of the use (or nonuse) of buprenorphine. Therefore, we conducted an additional sensitivity analysis excluding health service use factors from our final model to ensure the robustness of our findings.
Results from the sensitivity analyses were similar to the main findings (supplemental Table S5 ). Furthermore, we were unable to examine the association between the identified trajectories and relevant clinical 3.2 | Patterns of health service use, buprenorphine therapy, and quality of care
In Table 2 , compared to early initiators with persistently high adherence, late initiators or early initiators with declining adherence or early discontinuation had a higher hospitalization rate (9.1%-14.8% vs 6.7%, P < .001) during pregnancy. Early initiators with declining adherence or early discontinuation or late initiators with low-to-moderate adherence also had fewer outpatient visits (9.5-9.9 vs 11.3, P < .0001).
Compared to early initiators with persistently high adherence, the other 5 trajectory groups, on average, used a lower buprenorphine daily dose (14.7-16.5 vs 17.6 mg/day, P < .0001). Overall, 30% to 40% of women received behavioral counseling, and 67% to 77% had a urine drug test during pregnancy. Abbreviations: OUD, opioid use disorders; TANF, temporary assistance for the needy families.
Comparison between 6 trajectory groups: *P < .05. **P < .01. ***P < .001. † P < .0001.
a Includes diagnosis of dependence on illicit substances other than opioids (cocaine, cannabis, amphetamine, hallucinogen, other sedatives and other substances) or a diagnosis of "antepartum drug dependence," "maternal drug dependence at delivery," or "postpartum drug dependence" (see supplemental  Table S1 ).
b Mental health disorders include major depression disorder, bipolar disorder, and schizophrenia (see supplemental Table S1 ).
c Adverse pregnancy history includes diagnosis of history of preterm labor or delivery, or other high-risk pregnancy. Comparison between 6 trajectory groups: *P < .05. **P < .01. ***P < .001. † P < .0001. a With unique drug ingredients.
| Factors associated with specific buprenorphine trajectories: multivariable multinomial logistic regression
b Six hundred thirteen unique prescribers who wrote at least 1 buprenorphine prescription to the women in our study cohort (21.4% of buprenorphine claims had missing prescriber information).
c
The average dose of buprenorphine during the first trimester was not applicable for women who were later initiators.
| Post hoc analysis: proportions of all-cause ED visits and/or hospitalization across identified trajectories
As shown in Table 3 , late initiators with low-to-moderate adherence (37. The major strength of our study is the use of a group-based trajectory model to examine longitudinal buprenorphine refill patterns Four groups initiated buprenorphine during the first trimester of the pregnancy (early initiators): 31.6% with persistently high adherence (ie, persistently having a high PDC >0.8), 15.1% with moderate-to-high adherence (ie, initiating with a moderate PDC between 0.4 and 0.8 and increasing to a high PDC >0.8), 10.5% with declining adherence (ie, initiating with a moderate PDC but declining overtime to a low PDC <0.4), and 16.7% with early discontinuation (ie, initiating with a low PDC and discontinued before the third trimester). Two groups did not initiate buprenorphine until midsecond or third trimester (late initiators): 13.5% had moderate-to-high adherence (initiating with a moderate PDC, increasing to a high PDC in the third trimester and then decreasing to a moderate PDC postdelivery), 12.6% had low-to-moderate adherence (initiating with a low PDC and increasing to a moderate PDC).
*P < .0001 for the comparison across 6 groups.
over time, rather than using a single adherence measure (eg, average proportion of days covered during pregnancy) or an arbitrary cutpoint for discontinuation (eg, a gap in treatment for ≥30 days Given that premature discontinuation of buprenorphine may elevate the risk of relapse to opioid use and adverse obstetric and neonatal outcomes, 3, 4 Medicaid programs might consider investing in programs that offer woman-centered services tailored to patient needs and patient risk profiles to boost patient adherence and improve retention rates, especially among early initiators with early discontinuation and late initiators with low-to-moderate adherence. 39, 40 Several factors were identified that could be used to target patients at high risk of late initiation or early buprenorphine discontinuation including younger age, racial/ethnic minority groups, rural residency, lack of OUD diagnoses, nonopioid substance use disorder, and alcohol use disorder during pregnancy. In addition, late initiators (regardless of their adherence levels) and early initiators with early discontinuation had more inpatient visits and a lower mean buprenorphine daily dose during pregnancy. Given an increase in apparent clearance of buprenorphine during pregnancy, dose escalation of buprenorphine is suggested. 41 Clinicians may consider split dosing in patients complaining of discomfort and craving in the afternoon/evening to prevent relapse. 42, 43 Approximately 40% of our cohort had comorbid mental health disorders. Psychosocial treatment is recommended, and several meta-analyses showed the safety of selective serotonin reuptake inhibitors (SSRIs) in pregnancy (except paroxetine with an increased risk of cardiac defects). 44 Our study has several limitations. First, our study relied on administrative billing data that lacked laboratory results and sociobehavioral information. In the absence of data on timing of conception calculated from the last menstrual period, we applied the delivery date algorithm (ie, 280 days prior to the delivery date) that was used in the US NCQA's quality measures of prenatal and postpartum care. 13 In a validation study of the conception date, 45 applying the delivery datebased algorithm to examine prescription drug exposure in the first trimester for women without preterm births or pregnancy complications was accurate (sensitivity~92% and specificity~98%). Nevertheless, the sensitivity for the delivery date algorithm among women with preterm deliveries was low (66%). 45 Women with preterm deliveries may be misclassified as late initiators, although the extent to which this would bias our estimates is unknown. Potential unmeasured confounders also cannot be ruled out from our observational study. Second, similar to all claims-based measures of adherence, it is unknown whether the dispensed drugs were actually consumed by the patients. Medicaid are similar to those seen in other state Medicaid programs. 48 Pregnancy is a transformative state (both biologically and socially) that may provide a "window of opportunity" for OUD treatment and provide enormous potential for behavioral changes for this vulnerable population. 49 Our study showed 6 unique trajectories of longitudinal buprenorphine refills among pregnant Medicaid-enrolled women in Pennsylvania. These trajectories and associated factors may be further used to develop more targeted interventions to improve care and health outcomes among pregnant women with OUD.
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